Status:
TERMINATED
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Medivation, Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
Detailed Description
This study was terminated on May 7, 2010 as part of modification of the dimebon development plan following lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was no...
Eligibility Criteria
Inclusion
- Completion of previous Phase 3 Dimebon study (B1451027).
Exclusion
- Have any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
649 Patients enrolled
Trial Details
Trial ID
NCT00939783
Start Date
September 1 2009
End Date
August 1 2010
Last Update
November 14 2012
Active Locations (105)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
2
Pfizer Investigational Site
Northport, Alabama, United States, 35476
3
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
4
Pfizer Investigational Site
Oceanside, California, United States, 92056